Genome-based therapeutics: targeted drug discovery and development : workshop summary
"The number of new drug approvals has remained reasonably steady for the past 50 years at around 20 to 30 per year, while at the same time the total spending on health-related research and development has tripled since 1990. There are many suspected causes for this trend, including increases in...
Saved in:
| Other Authors: | , |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Washington, District of Columbia
National Academies Press
[2012]
|
| Subjects: | |
| Summary: | "The number of new drug approvals has remained reasonably steady for the past 50 years at around 20 to 30 per year, while at the same time the total spending on health-related research and development has tripled since 1990. There are many suspected causes for this trend, including increases in regulatory barriers, the rising costs of scientific inquiry, a decrease in research and development efficiency, the downstream effects of patient expirations on investment, and the lack of production models that have successfully incorporated new technology. Regardless, this trajectory is not economically sustainable for the businesses involved, and, in response, many companies are turning toward collaborative models of drug development, whether with other industrial firms, academia, or government. Introducing greater efficiency and knowledge into these new models and aligning incentives among participants may help to reverse the trends highlighted above, while producing more effective drugs in the process. Genome-based therapeutics explains that new technologies have the potential to open up avenues of development and to identify new drug targets to pursue. Specifically, improved validation of gene-disease associations through genomics research has the potential to revolutionize drug production and lower development costs. Genetic information has helped developers by increasing their understanding of the mechanisms of disease as well as individual patients' reactions to their medications. There is a need to identify the success factors for the various models that are being developed, whether they are industry-led, academia-led, or collaborations between the two. Genome-Based Therapeutics summarizes a workshop that was held on March 21, 2012, titled New paradigms in drug discovery: how genomic data are being used to revolutionize the drug discovery and development process. At this workshop the goal was to examine the general approaches being used to apply successes achieved so far, and the challenges ahead"--Publisher's description |
| Item Description: | Description based on print version record |
| Physical Description: | 1 online resource (109 pages) illustrations |
| ISBN: | 9780309260244 0309260248 9780309260213 9780309260251 |
Staff View
MARC
| LEADER | 00000nam a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV044056122 | ||
| 003 | DE-604 | ||
| 005 | 20250612 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 170217s2012 xx a||| o|||| 10||| eng d | ||
| 020 | |a 9780309260244 |c Print |9 978-0-309-26024-4 | ||
| 020 | |a 0309260248 |c Print |9 0-309-26024-8 | ||
| 020 | |a 9780309260213 |c Print |9 978-0-309-26021-3 | ||
| 020 | |a 9780309260251 |c ebook |9 978-0-309-26025-1 | ||
| 035 | |a (ZDB-30-PAD)EBC3379240 | ||
| 035 | |a (ZDB-89-EBL)EBL3379240 | ||
| 035 | |a (ZDB-38-EBR)ebr10863895 | ||
| 035 | |a (OCoLC)817900348 | ||
| 035 | |a (DE-599)BVBBV044056122 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 082 | 0 | |a 615.1 |2 23 | |
| 245 | 1 | 0 | |a Genome-based therapeutics |b targeted drug discovery and development : workshop summary |c Adam C. Berger and Steve Olson, Rapporteurs ; Roundtable on Translating Genomic-Based Research for Health, Board on Health Sciences Policy, Institute of Medicine of the National Academies |
| 246 | 1 | 3 | |a Targeted drug discovery and development |
| 264 | 1 | |a Washington, District of Columbia |b National Academies Press |c [2012] | |
| 264 | 4 | |c © 2012 | |
| 300 | |a 1 online resource (109 pages) |b illustrations | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Description based on print version record | ||
| 520 | |a "The number of new drug approvals has remained reasonably steady for the past 50 years at around 20 to 30 per year, while at the same time the total spending on health-related research and development has tripled since 1990. There are many suspected causes for this trend, including increases in regulatory barriers, the rising costs of scientific inquiry, a decrease in research and development efficiency, the downstream effects of patient expirations on investment, and the lack of production models that have successfully incorporated new technology. Regardless, this trajectory is not economically sustainable for the businesses involved, and, in response, many companies are turning toward collaborative models of drug development, whether with other industrial firms, academia, or government. | ||
| 520 | |a Introducing greater efficiency and knowledge into these new models and aligning incentives among participants may help to reverse the trends highlighted above, while producing more effective drugs in the process. Genome-based therapeutics explains that new technologies have the potential to open up avenues of development and to identify new drug targets to pursue. Specifically, improved validation of gene-disease associations through genomics research has the potential to revolutionize drug production and lower development costs. Genetic information has helped developers by increasing their understanding of the mechanisms of disease as well as individual patients' reactions to their medications. There is a need to identify the success factors for the various models that are being developed, whether they are industry-led, academia-led, or collaborations between the two. | ||
| 520 | |a Genome-Based Therapeutics summarizes a workshop that was held on March 21, 2012, titled New paradigms in drug discovery: how genomic data are being used to revolutionize the drug discovery and development process. At this workshop the goal was to examine the general approaches being used to apply successes achieved so far, and the challenges ahead"--Publisher's description | ||
| 650 | 4 | |a Drugs |z United States |x Design |v Congresses | |
| 650 | 4 | |a Pharmaceutical technology |z United States |v Congresses | |
| 650 | 4 | |a Pharmaceutical industry |z United States |v Congresses | |
| 650 | 4 | |a Genomics |z United States |v Congresses | |
| 651 | 4 | |a USA | |
| 655 | 7 | |0 (DE-588)1071861417 |a Konferenzschrift |2 gnd-content | |
| 700 | 1 | |a Berger, Adam C. |0 (DE-588)107101160X |4 ctb | |
| 700 | 1 | |a Olson, Steve |d 1956- |0 (DE-588)124424317 |4 ctb | |
| 710 | 2 | |a Institute of Medicine (U.S.) |e Roundtable on Translating Genomic-Based Research for Health |4 oth | |
| 710 | 2 | |a Institute of Medicine (U.S.) |e Board on Health Sciences Policy |4 oth | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |a Genome-based therapeutics : targeted drug discovery and development : workshop summary |
| 912 | |a ZDB-30-PAD | ||
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-029462967 | |
Record in the Search Index
| _version_ | 1834732058012811264 |
|---|---|
| adam_text | |
| any_adam_object | |
| author2 | Berger, Adam C. Olson, Steve 1956- |
| author2_role | ctb ctb |
| author2_variant | a c b ac acb s o so |
| author_GND | (DE-588)107101160X (DE-588)124424317 |
| author_facet | Berger, Adam C. Olson, Steve 1956- |
| building | Verbundindex |
| bvnumber | BV044056122 |
| collection | ZDB-30-PAD |
| ctrlnum | (ZDB-30-PAD)EBC3379240 (ZDB-89-EBL)EBL3379240 (ZDB-38-EBR)ebr10863895 (OCoLC)817900348 (DE-599)BVBBV044056122 |
| dewey-full | 615.1 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.1 |
| dewey-search | 615.1 |
| dewey-sort | 3615.1 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a2200000zc 4500</leader><controlfield tag="001">BV044056122</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20250612</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">170217s2012 xx a||| o|||| 10||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780309260244</subfield><subfield code="c">Print</subfield><subfield code="9">978-0-309-26024-4</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0309260248</subfield><subfield code="c">Print</subfield><subfield code="9">0-309-26024-8</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780309260213</subfield><subfield code="c">Print</subfield><subfield code="9">978-0-309-26021-3</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780309260251</subfield><subfield code="c">ebook</subfield><subfield code="9">978-0-309-26025-1</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-30-PAD)EBC3379240</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-89-EBL)EBL3379240</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-38-EBR)ebr10863895</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)817900348</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV044056122</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.1</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Genome-based therapeutics</subfield><subfield code="b">targeted drug discovery and development : workshop summary</subfield><subfield code="c">Adam C. Berger and Steve Olson, Rapporteurs ; Roundtable on Translating Genomic-Based Research for Health, Board on Health Sciences Policy, Institute of Medicine of the National Academies</subfield></datafield><datafield tag="246" ind1="1" ind2="3"><subfield code="a">Targeted drug discovery and development</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Washington, District of Columbia</subfield><subfield code="b">National Academies Press</subfield><subfield code="c">[2012]</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">© 2012</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (109 pages)</subfield><subfield code="b">illustrations</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Description based on print version record</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">"The number of new drug approvals has remained reasonably steady for the past 50 years at around 20 to 30 per year, while at the same time the total spending on health-related research and development has tripled since 1990. There are many suspected causes for this trend, including increases in regulatory barriers, the rising costs of scientific inquiry, a decrease in research and development efficiency, the downstream effects of patient expirations on investment, and the lack of production models that have successfully incorporated new technology. Regardless, this trajectory is not economically sustainable for the businesses involved, and, in response, many companies are turning toward collaborative models of drug development, whether with other industrial firms, academia, or government.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Introducing greater efficiency and knowledge into these new models and aligning incentives among participants may help to reverse the trends highlighted above, while producing more effective drugs in the process. Genome-based therapeutics explains that new technologies have the potential to open up avenues of development and to identify new drug targets to pursue. Specifically, improved validation of gene-disease associations through genomics research has the potential to revolutionize drug production and lower development costs. Genetic information has helped developers by increasing their understanding of the mechanisms of disease as well as individual patients' reactions to their medications. There is a need to identify the success factors for the various models that are being developed, whether they are industry-led, academia-led, or collaborations between the two.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Genome-Based Therapeutics summarizes a workshop that was held on March 21, 2012, titled New paradigms in drug discovery: how genomic data are being used to revolutionize the drug discovery and development process. At this workshop the goal was to examine the general approaches being used to apply successes achieved so far, and the challenges ahead"--Publisher's description</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs</subfield><subfield code="z">United States</subfield><subfield code="x">Design</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical technology</subfield><subfield code="z">United States</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical industry</subfield><subfield code="z">United States</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Genomics</subfield><subfield code="z">United States</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="651" ind1=" " ind2="4"><subfield code="a">USA</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)1071861417</subfield><subfield code="a">Konferenzschrift</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Berger, Adam C.</subfield><subfield code="0">(DE-588)107101160X</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Olson, Steve</subfield><subfield code="d">1956-</subfield><subfield code="0">(DE-588)124424317</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">Institute of Medicine (U.S.)</subfield><subfield code="e">Roundtable on Translating Genomic-Based Research for Health</subfield><subfield code="4">oth</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">Institute of Medicine (U.S.)</subfield><subfield code="e">Board on Health Sciences Policy</subfield><subfield code="4">oth</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="a">Genome-based therapeutics : targeted drug discovery and development : workshop summary</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-30-PAD</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-029462967</subfield></datafield></record></collection> |
| genre | (DE-588)1071861417 Konferenzschrift gnd-content |
| genre_facet | Konferenzschrift |
| geographic | USA |
| geographic_facet | USA |
| id | DE-604.BV044056122 |
| illustrated | Illustrated |
| indexdate | 2025-06-12T14:00:41Z |
| institution | BVB |
| isbn | 9780309260244 0309260248 9780309260213 9780309260251 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-029462967 |
| oclc_num | 817900348 |
| open_access_boolean | |
| physical | 1 online resource (109 pages) illustrations |
| psigel | ZDB-30-PAD |
| publishDate | 2012 |
| publishDateSearch | 2012 |
| publishDateSort | 2012 |
| publisher | National Academies Press |
| record_format | marc |
| spelling | Genome-based therapeutics targeted drug discovery and development : workshop summary Adam C. Berger and Steve Olson, Rapporteurs ; Roundtable on Translating Genomic-Based Research for Health, Board on Health Sciences Policy, Institute of Medicine of the National Academies Targeted drug discovery and development Washington, District of Columbia National Academies Press [2012] © 2012 1 online resource (109 pages) illustrations txt rdacontent c rdamedia cr rdacarrier Description based on print version record "The number of new drug approvals has remained reasonably steady for the past 50 years at around 20 to 30 per year, while at the same time the total spending on health-related research and development has tripled since 1990. There are many suspected causes for this trend, including increases in regulatory barriers, the rising costs of scientific inquiry, a decrease in research and development efficiency, the downstream effects of patient expirations on investment, and the lack of production models that have successfully incorporated new technology. Regardless, this trajectory is not economically sustainable for the businesses involved, and, in response, many companies are turning toward collaborative models of drug development, whether with other industrial firms, academia, or government. Introducing greater efficiency and knowledge into these new models and aligning incentives among participants may help to reverse the trends highlighted above, while producing more effective drugs in the process. Genome-based therapeutics explains that new technologies have the potential to open up avenues of development and to identify new drug targets to pursue. Specifically, improved validation of gene-disease associations through genomics research has the potential to revolutionize drug production and lower development costs. Genetic information has helped developers by increasing their understanding of the mechanisms of disease as well as individual patients' reactions to their medications. There is a need to identify the success factors for the various models that are being developed, whether they are industry-led, academia-led, or collaborations between the two. Genome-Based Therapeutics summarizes a workshop that was held on March 21, 2012, titled New paradigms in drug discovery: how genomic data are being used to revolutionize the drug discovery and development process. At this workshop the goal was to examine the general approaches being used to apply successes achieved so far, and the challenges ahead"--Publisher's description Drugs United States Design Congresses Pharmaceutical technology United States Congresses Pharmaceutical industry United States Congresses Genomics United States Congresses USA (DE-588)1071861417 Konferenzschrift gnd-content Berger, Adam C. (DE-588)107101160X ctb Olson, Steve 1956- (DE-588)124424317 ctb Institute of Medicine (U.S.) Roundtable on Translating Genomic-Based Research for Health oth Institute of Medicine (U.S.) Board on Health Sciences Policy oth Erscheint auch als Druck-Ausgabe Genome-based therapeutics : targeted drug discovery and development : workshop summary |
| spellingShingle | Genome-based therapeutics targeted drug discovery and development : workshop summary Drugs United States Design Congresses Pharmaceutical technology United States Congresses Pharmaceutical industry United States Congresses Genomics United States Congresses |
| subject_GND | (DE-588)1071861417 |
| title | Genome-based therapeutics targeted drug discovery and development : workshop summary |
| title_alt | Targeted drug discovery and development |
| title_auth | Genome-based therapeutics targeted drug discovery and development : workshop summary |
| title_exact_search | Genome-based therapeutics targeted drug discovery and development : workshop summary |
| title_full | Genome-based therapeutics targeted drug discovery and development : workshop summary Adam C. Berger and Steve Olson, Rapporteurs ; Roundtable on Translating Genomic-Based Research for Health, Board on Health Sciences Policy, Institute of Medicine of the National Academies |
| title_fullStr | Genome-based therapeutics targeted drug discovery and development : workshop summary Adam C. Berger and Steve Olson, Rapporteurs ; Roundtable on Translating Genomic-Based Research for Health, Board on Health Sciences Policy, Institute of Medicine of the National Academies |
| title_full_unstemmed | Genome-based therapeutics targeted drug discovery and development : workshop summary Adam C. Berger and Steve Olson, Rapporteurs ; Roundtable on Translating Genomic-Based Research for Health, Board on Health Sciences Policy, Institute of Medicine of the National Academies |
| title_short | Genome-based therapeutics |
| title_sort | genome based therapeutics targeted drug discovery and development workshop summary |
| title_sub | targeted drug discovery and development : workshop summary |
| topic | Drugs United States Design Congresses Pharmaceutical technology United States Congresses Pharmaceutical industry United States Congresses Genomics United States Congresses |
| topic_facet | Drugs United States Design Congresses Pharmaceutical technology United States Congresses Pharmaceutical industry United States Congresses Genomics United States Congresses USA Konferenzschrift |
| work_keys_str_mv | AT bergeradamc genomebasedtherapeuticstargeteddrugdiscoveryanddevelopmentworkshopsummary AT olsonsteve genomebasedtherapeuticstargeteddrugdiscoveryanddevelopmentworkshopsummary AT instituteofmedicineus genomebasedtherapeuticstargeteddrugdiscoveryanddevelopmentworkshopsummary AT bergeradamc targeteddrugdiscoveryanddevelopment AT olsonsteve targeteddrugdiscoveryanddevelopment AT instituteofmedicineus targeteddrugdiscoveryanddevelopment |